Moore Capital Management, LP Entrada Therapeutics, Inc. Transaction History
Moore Capital Management, LP
- $4.85 Billion
- Q3 2024
A detailed history of Moore Capital Management, LP transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Moore Capital Management, LP holds 105,000 shares of TRDA stock, worth $2 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
105,000
Previous 105,000
-0.0%
Holding current value
$2 Million
Previous $1.5 Million
12.17%
% of portfolio
0.03%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$92.6 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$84.3 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$83.9 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$58.1 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$32.6 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $597M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...